Meta-analysis of clinical trials showed that blood pressure reduction is frequently observed with chronic administration of GLP-1R agonists in patients with T2DM (Wang et al., 2013; Sun et al., 2015). This evidence concerns the gene GLP1R and type 2 diabetes mellitus.